In the case of the etiological gene editing industry, hope is from KJ MULDOON, which is small, smiling and fuzzy earlier this month.
In just six months, KJ received customized gene editing to modify his unique mutation. He was not treated, researchers explained at New Orleans’ annual US genes and cell therapy meetings. But he was able to resume normal perception and is no longer in the liver transplant path.
This news could not be more welcome or more difficult in the field. For three years, genetic editing was freely seen due to dismissal, closed, closed programs and sinking stocks. Finally, we reminded me of what the 10 -year progress can be provided in the form of striped pajamas. “How great is our guy?” Nessan Bermingham, who co -founded and led Intellia, one of the first CRISPR companies until 2017.
This article applies only to STAT+ subscribers.
Join STAT+to unlock this article (daily coverage and analysis of the biotech sector).
Is there an account already? Log in
Look at all plans
